- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Patent holdings for IPC class A61P 9/04
Total number of patents in this class: 1998
10-year publication summary
|
80
|
75
|
75
|
114
|
148
|
140
|
157
|
187
|
164
|
59
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Daiichi Sankyo Company, Limited | 1829 |
50 |
| Takeda Pharmaceutical Company Limited | 2961 |
40 |
| Cytokinetics, Inc. | 259 |
38 |
| Novartis AG | 11238 |
34 |
| Amgen Inc. | 3779 |
30 |
| Bristol-myers Squibb Company | 5080 |
27 |
| Osaka University | 3143 |
26 |
| Mitsubishi Tanabe Pharma Corporation | 579 |
21 |
| Cardioxyl Pharmaceuticals, Inc. | 49 |
19 |
| Boehringer Ingelheim International GmbH | 4629 |
18 |
| Banyu Pharmaceutical Co., Ltd. | 107 |
18 |
| Boehringer Ingelheim Vetmedica GmbH | 1290 |
17 |
| Bayer Pharma AG | 1096 |
17 |
| AstraZeneca AB | 3042 |
15 |
| Japan Tobacco Inc. | 3225 |
15 |
| MyoKardia, Inc. | 97 |
15 |
| Shionogi & Co., Ltd. | 914 |
14 |
| Sunshine Lake Pharma Co., Ltd. | 542 |
13 |
| Kyushu University, National University Corporation | 1572 |
11 |
| Imbria Pharmaceuticals, Inc. | 60 |
11 |
| Other owners | 1549 |